Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
S Han, Y Lu - European Journal of Medicinal Chemistry, 2023 - Elsevier
Human immunodeficiency virus (HIV) is the etiological agent of acquired immunodeficiency
syndrome (AIDS). Nowadays, FDA has approved over thirty antiretroviral drugs grouped in …
syndrome (AIDS). Nowadays, FDA has approved over thirty antiretroviral drugs grouped in …
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
T Loosli, S Hossmann, SM Ingle, H Okhai… - The Lancet …, 2023 - thelancet.com
Background The widespread use of the integrase strand transfer inhibitor (INSTI)
dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate …
dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate …
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study
Background Many countries are now replacing non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing …
inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing …
Roadmap for achieving universal antiretroviral treatment
Modern antiretroviral therapy safely, potently, and durably suppresses human
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
Dolutegravir resistance in Malawi's national HIV treatment program
JJ van Oosterhout, C Chipungu… - Open Forum …, 2022 - academic.oup.com
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed
HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020 …
HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020 …
Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-line ART in Cameroon: an evidence of a successful …
ENJ Semengue, J Fokam, NK Etame, E Molimbou… - Viruses, 2022 - mdpi.com
To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared
first-line virological response (VR) under tenofovir+ lamivudine+ dolutegravir (TLD) …
first-line virological response (VR) under tenofovir+ lamivudine+ dolutegravir (TLD) …
HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola
CS Sebastião, AB Abecasis, D Jandondo… - Scientific Reports, 2024 - nature.com
The surveillance of drug resistance in the HIV-1 naïve population remains critical to
optimizing the effectiveness of antiretroviral therapy (ART), mainly in the era of integrase …
optimizing the effectiveness of antiretroviral therapy (ART), mainly in the era of integrase …
Transitioning to dolutegravir in a programmatic setting: Virological outcomes and associated factors among treatment-naïve patients with HIV-1 in the Kilombero and …
AJ Ntamatungiro, A Eichenberger… - Open forum …, 2023 - academic.oup.com
Background Virological outcome data after programmatic transition from non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual map** of a complex adaptive system based on multi-disciplinary expert …
A Kiekens, B Dierckx de Casterlé, G Pellizzer… - BMC Public Health, 2022 - Springer
Background HIV drug resistance (HIVDR) continues to threaten the effectiveness of
worldwide antiretroviral therapy (ART). Emergence and transmission of HIVDR are driven by …
worldwide antiretroviral therapy (ART). Emergence and transmission of HIVDR are driven by …
Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with human immunodeficiency virus treatment outcomes in sub …
Background Dolutegravir is being rolled out globally as part of preferred antiretroviral
therapy (ART) regimens, including among treatment-experienced patients. The role of viral …
therapy (ART) regimens, including among treatment-experienced patients. The role of viral …